1. Home
  2. FOXX vs CVM Comparison

FOXX vs CVM Comparison

Compare FOXX & CVM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Foxx Development Holdings Inc.

FOXX

Foxx Development Holdings Inc.

HOLD

Current Price

$5.15

Market Cap

34.0M

Sector

N/A

ML Signal

HOLD

Logo Cel-Sci Corporation

CVM

Cel-Sci Corporation

HOLD

Current Price

$3.24

Market Cap

32.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
FOXX
CVM
Founded
2017
1983
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
34.0M
32.4M
IPO Year
N/A
1996

Fundamental Metrics

Financial Performance
Metric
FOXX
CVM
Price
$5.15
$3.24
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
9.0K
30.4K
Earning Date
05-14-2026
05-14-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$264,033.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
65.45
52 Week Low
$1.71
$0.18
52 Week High
$8.70
$13.48

Technical Indicators

Market Signals
Indicator
FOXX
CVM
Relative Strength Index (RSI) 61.58 41.90
Support Level $4.90 $3.34
Resistance Level $5.42 $6.75
Average True Range (ATR) 0.37 0.28
MACD 0.10 0.03
Stochastic Oscillator 76.57 49.43

Price Performance

Historical Comparison
FOXX
CVM

About FOXX Foxx Development Holdings Inc.

Foxx Development Holdings Inc is a consumer electronics and integrated Internet-of-Things (IoT) solution company catering to both retail and institutional clients. With robust research and development capabilities and a strategic commitment to cultivating long-term partnerships with mobile network operators, distributors, and suppliers. Its products include tablets, smartphones, wearables, and other high-quality communication terminals. The company's current revenue stream is derived from the sales of tablets and smartphones.

About CVM Cel-Sci Corporation

CEL-SCI Corp is a late clinical-stage biotechnology company dedicated to research and development directed at improving the treatment of cancer and other diseases by using the immune system, the body's natural defense system. The company is focused on the development of the following product candidates and technologies: 1) Multikine, an investigational Phase 3 immunotherapy under development for the potential treatment of certain head and neck cancers; 2) LEAPS (Ligand Epitope Antigen Presentation System) technology, for the potential treatment of rheumatoid arthritis.

Share on Social Networks: